monoamine oxidase

Also found in: Dictionary, Thesaurus, Financial, Encyclopedia, Wikipedia.


an amine containing only one amino group.
monoamine oxidase (MAO) a copper-containing enzyme that deaminates monoamines such as dopamine, epinephrine, norepinephrine, and serotonin. See also monoamine oxidase inhibitor.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

a·mine ox·i·dase

1. an oxidoreductase containing copper, and perhaps pyridoxal phosphate, and carrying out the same reaction as amine oxidase (flavin-containing). Synonym(s): diamine oxidase, histaminase
2. an oxidoreductase containing flavin and oxidizing amines with the aid of O2 and water to aldehydes or ketones with the release of NH3 and H2O2. Acted upon by antidepressants. Synonym(s): adrenaline oxidase, monoamine oxidase, tyraminase, tyramine oxidase
Farlex Partner Medical Dictionary © Farlex 2012

monoamine oxidase

n. Abbr. MAO
An enzyme that catalyzes the oxidative breakdown of monoamines such as norepinephrine and serotonin, thus regulating synaptic transmission of monoamine neurotransmitters in the nervous system.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

monoamine oxidase

MAO, one of a group of enzymes found in brain cells, in peripheral adrenergic and dopaminergic nerve endings and in the intestinal wall and liver. These enzymes play an important part in the breakdown of the neurotransmitters NORADRENALINE, DOPAMINE and serotonin (5-hydroxytryptamine). Non-selective inhibition of these enzymes will elevate mood. Selective MAO-A enzymes act on serotonin; selective MAO-B inhibitor drugs act on phenylethylamine in the glial cells of the brain and elsewhere. The selective MAO-A inhibitor drugs are used to treat DEPRESSION and anxiety; selective MAO-B inhibitors are used to treat Parkinsonism.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Babelova et al., "Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta," Hypertension, vol.
Monoamine oxidase (MAO) is an enzyme that reduces neurotransmitters to their metabolites for excretion, thus providing an essential component of the normal cycle of transmitter production and excretion.
This could have been anticipated since inhibition of monoamine oxidase leads to increased availability of norepinephrine and serotonin besides dopamine.
Monoamine oxidase A is the main enzyme in the brain that breaks down serotonin, norepinephrine and dopamine, which have been shown to contribute to the "fight or flight" impulse by raising heart rates and increasing blood and oxygen flow.
Monoamine oxidase (MAO) and some other brain neurotransmitters play a complicated role in the development of female sexual dysfunction symptoms.
(1.) Balon R, Mufti R, Arfken CL A survey of prescribing practices for monoamine oxidase inhibitors.
Masini et al., "Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury," Circulation, vol.
DA is converted to DOPAC intraneuronally after re-uptake, whereas extraneuronal DA is converted to HVA by the enzymes catechol-O-methyltransferase and monoamine oxidase. The lack of change in DOPAC and HVA could reflect the relatively modest nature of the changes in DA, leaving a sufficiently high concentration of DA in the intracellular space to maintain constant levels of DOPAC and HVA production.
WASHINGTON -- A transdermal patch containing the selective monoamine oxidase inhibitor selegiline applied daily appeared effective and well tolerated in a pilot study of children and adolescents with attention-deficit hyperactivity disorder.
Most of these medications effectively treat depression by increasing available levels of monoamine neurotransmitters through monoamine oxidase inhibition, reuptake inhibition, or neurotransmitter binding.
Researchers at Birmingham University looked at 17 trials involving a group of drugs called monoamine oxidase type B inhibitors (MAOBIs), which are used to slow the progression of Parkinson's.
Weight gain is seen with SSRIs but is more common with tri-cyclic antidepressants, monoamine oxidase inhibitors, and mirtazapine.